Nicotinic acetylcholine receptor subtypes α4β2 and α6β2 (nAChR α4β2; nAChR α6β2)

Nicotinic acetylcholine receptors containing alpha-4 and beta-2 (α4β2) or alpha-6 and beta-2 (α6β2) subunits are pentameric ligand-gated ion channels widely expressed in the central nervous system. **α4β2 nAChRs** are the predominant high-affinity binding sites for nicotine in the brain, mediating many of nicotine’s rewarding and addictive effects and playing key roles in cognitive function and attention[4][3][5]. **α6β2 nAChRs** are found in dopaminergic pathways and are implicated in the modulation of dopamine release as well as pain signaling[2]. Both subtypes are therapeutic targets for neurodegenerative disease, smoking cessation, and cognitive disorders. Activation leads to rapid ion flux (Na⁺, K⁺, sometimes Ca²⁺), depolarizing neurons and facilitating neurotransmitter release. Drugs targeting these receptors act as agonists, partial agonists, or antagonists, and are used or investigated in treatments for nicotine dependence, schizophrenia, Parkinson’s disease, and pain[3][4][2][5][7]. Both subtypes are subjects of intense research for selective modulation due to physiological importance and safety concerns around addiction and neurological side effects.\n\n**Note:** \nThis response provides separating two distinct canonical forms for α4β2 and α6β2 as per conventions, with detailed attributes mapped for both. The α6β2 receptor is less studied than α4β2, but many principles and drug interactions apply similarly. Where evidence for α6β2 is more limited, information is based on known nAChR biology and structural/functional analogies[2].

Other names

α4β2 nicotinic receptorα6β2 nicotinic receptorα4β2 nAChRα6β2 nAChRNicotinic acetylcholine receptor α4β2Nicotinic acetylcholine receptor α6β2

Agonists mimic acetylcholine and activate the receptor, increasing Na⁺ and K⁺ ion flux across the membrane, leading to neuron depolarization\nPartial agonists produce submaximal receptor activation\nAntagonists block acetylcholine and nicotine binding, inhibiting receptor activation\nSome drugs (like varenicline) act as partial agonists at α4β2, reducing craving by providing mild stimulation and blocking nicotine’s full effect